Ulrich Pilatus1, Oliver Bhr2, Joachim Steinbach2, Elke Hattingen1
Neuroradiology, Goethe University Frankfurt, Frankfurt/Main,
31P and 1H MRSI was performed on recurrent glioblastomas prior and following treatment with the antiangiogenic agent Bevazizumab. Untreated tumor tissue revealed decreased glycerophosphocholine (GPE) and increased pH. In patients who were responding to the therapy (RANO criteria), both parameters reverted to normal levels within 8 weeks of treatment.